Enoxaparin for VTE thromboprophylaxis during inpatient rehabilitation care: assessment of the standard fixed dosing regimen.

ABSTRACT:

Background

We aimed to examine the efficiency of fixed daily dose enoxaparin (40 mg) thromboprophylaxis strategy for patients undergoing inpatient rehabilitation.

Methods

This was an observational, prospective, cohort study that included 63 hospitalized patients undergoing rehabilitative treatment following sub-acute ischemic stroke (SAIS) or spinal cord injury (SCI), with an indication for thromboprophylaxis. Anti-Xa level measured three hours post-drug administration (following three consecutive days of enoxaparin treatment or more) was utilised to assess in vivo enoxaparin activity. An anti-Xa level between 0.2-0.5 U/ml was considered evidence of effective antithrombotic activity.

Results

We found sub-prophylactic levels of anti-Xa (<0.2 U/ml) in 19% (12/63). Resul

SUBMITTER: Haim A 

PROVIDER: S-EPMC10782744 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature